Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression

被引:88
作者
Kupferman, ME
Fini, ME
Muller, WJ
Weber, R
Cheng, Y
Muschel, RJ
机构
[1] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA
[3] Tufts Univ, Sch Med, New England Eye Ctr, Vis Res Labs, Boston, MA 02111 USA
[4] McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON, Canada
[5] McMaster Univ, Dept Biol, Hamilton, ON, Canada
[6] McMaster Univ, Dept Pathol, Hamilton, ON, Canada
关键词
D O I
10.1016/S0002-9440(10)64815-8
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Matrix metalloproteinase 9 (MMP-9, also known as gelatinase B or 92-kd Type IV collagenase) is overexpressed in many human and murine cancers. We induced carcinomas in mice carrying a transgene that links the MMP-9 promoter to the reporter beta -galactosidase so that activation of the MMP-9 promoter would be indicated by beta -galactosidase. Mammary carcinomas were induced by mating the MMP-9 promoter reporter transgenic mice with mice carrying a transgene for murine mammary tumor virus promoter linked to polyoma middle T antigen, a transgene that leads to rapid development of mammary tumors in female mice. None of the hyperplastic mammary glands and. none of the carcinomas in situ expressed beta -galactosidase. However, all invasive tumors had evidence of beta -galactosidase expression. In addition to the breast carcinomas, a malignant teratoma in a female and a papillary adenocarcinoma in the pelvic region of a male arose and were also beta -galactosidase positive. We also induced skin tumors in the mice with the MMP-9 reporter transgene with 7, 12-dimethylbenz[a]anthracene (DMBA) treatment followed by phorbol 12 myristate 13-acetate (TPA). None of the papillomas or in situ carcinomas showed any beta -galactosidase expression, but expression was seen in invasive carcinoma, Although normal skin epithelial cells did not express beta -galactosidase, we did find staining in a few cells at the duct of the sebaceous gland at the base of the hair follicles. The MMP-9 reporter transgene did not lead to expression in the alveolar macrophages, confirming that additional upstream sequences are required for expression in macrophages. These experiments have revealed that MMP-9 promoter activity is induced coincident with invasion during tumor progression. Furthermore, this indicates that the more proximal upstream elements of the promoter are sufficient for MMP-9 transcription during tumor progression.
引用
收藏
页码:1777 / 1783
页数:7
相关论文
共 57 条
[31]   Gelatinase B/lacZ transgenic mice, a model for mapping gelatinase B expression during developmental and injury related tissue remodeling [J].
Mohan, R ;
Rinehart, WB ;
Bargagna-Mohan, P ;
Fini, ME .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (40) :25903-25914
[32]   Murine matrix metalloproteinase 9 gene -: 5′-upstream region contains cis-acting elements for expression in osteoclasts and migrating keratinocytes in transgenic mice [J].
Munaut, C ;
Salonurmi, T ;
Kontusaari, S ;
Reponen, P ;
Morita, T ;
Foidart, JM ;
Tryggvason, K .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (09) :5588-5596
[33]   HISTOPATHOLOGY OF TRANSGENIC MOUSE MAMMARY-TUMORS (A SHORT ATLAS) [J].
MUNN, RJ ;
WEBSTER, M ;
MULLER, WJ ;
CARDIFF, RD .
SEMINARS IN CANCER BIOLOGY, 1995, 6 (03) :153-158
[34]   Matrix metalloproteinases [J].
Nagase, H ;
Woessner, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (31) :21491-21494
[35]  
Neznanov N, 1999, CANCER RES, V59, P4242
[36]   Expression of gelatinases A and B, stromelysin-3 and matrilysin genes in breast carcinomas: clinico-pathological correlations [J].
Pacheco, MM ;
Mourao, M ;
Mantovani, EB ;
Nishimoto, IN ;
Brentani, MM .
CLINICAL & EXPERIMENTAL METASTASIS, 1998, 16 (07) :577-585
[37]  
PYKE C, 1992, CANCER RES, V52, P1336
[38]   Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer [J].
Remacle, AG ;
Noël, A ;
Duggan, C ;
McDermott, E ;
O'Higgins, N ;
Foidart, JM ;
Duffy, MJ .
BRITISH JOURNAL OF CANCER, 1998, 77 (06) :926-931
[39]  
Rha SY, 1998, ONCOL REP, V5, P875
[40]  
Rha SY, 1997, BREAST CANCER RES TR, V43, P175